Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1345 + Fluzone HD
- Development stage
- Phase 3
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1345 + Fluzone HD refers to the concomitant administration of Moderna's mRNA-1345 (mRESVIA) and Sanofi's Fluzone High-Dose (HD) Quadrivalent vaccine. mRNA-1345 is an mRNA-based vaccine encapsulated in lipid nanoparticles that encodes for the stabilized pre-fusion F glycoprotein of Respiratory Syncytial Virus (RSV), designed to prevent lower respiratory tract disease. Fluzone HD is an inactivated quadrivalent influenza vaccine containing 60 µg of hemagglutinin per strain (four times the dose of standard influenza vaccines), specifically indicated for adults aged 65 and older to provide enhanced protection against seasonal influenza. The co-administration of these two vaccines is being evaluated in Phase 3 clinical trials (e.g., NCT06060457) to assess safety, tolerability, and immunogenicity compared to sequential administration in the elderly population.
- Brand names
- Fluzone High-Dose Quadrivalent
- Other names
- RSV vaccine + High-Dose Influenza Vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)HA (Hemagglutinin)RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on mRNA-1345 + Fluzone HD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1345 + Fluzone HD.